Advanced cutaneous squamous cell carcinoma: lines of therapy
5 standard-of-care settings across 4 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | FRα | Risk group |
|---|---|---|---|
| Early / localised | 1 | · | 1 |
| Advanced, first line | 1 | · | · |
| Third line and beyond | · | 1 | · |
| Other settings | 1 | · | · |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Adjuvant after surgery and radiotherapy | Cemiplimab for high-risk disease (C-POST, 2025). | C-POST (NEJM 2025) | 85 | |
| Risk group | High-risk resectable disease | Excision with margin control or Mohs surgery, nodal evaluation, and postoperative radiotherapy for perineural invasion, positive margins or nodal disease; neoadjuvant cemiplimab to shrink large tumours before surgery. | NCCN Guidelines: Squamous Cell Skin Cancer | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Locally advanced or metastatic, first line | Cemiplimab (EMPOWER-CSCC-1), pembrolizumab (KEYNOTE-629) or cosibelimab; radiotherapy for symptomatic sites. | NCCN Guidelines: Squamous Cell Skin Cancer | 98 |
Third line and beyond
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| FRα | Immunotherapy-ineligible or refractory | Cetuximab with or without radiotherapy, platinum-based chemotherapy, capecitabine; clinical trials of RP1 with cemiplimab or photoimmunotherapy. | NCCN Guidelines: Squamous Cell Skin Cancer | 93 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Transplant recipients | Reduce immunosuppression and switch to sirolimus or everolimus where possible; PD-1 blockade only after weighing graft rejection risk; surgery and radiotherapy preferred. | NCCN Guidelines: Squamous Cell Skin Cancer | 91 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.